Search

Abstract Background To investigate the prognostic value of corpus uterine invasion (CUI) in cervical cancer (CC), and determine the necessity to incorporate it for staging. Methods A total of 809 cases of biopsy‐proven, non‐metastatic CC were identified from an academic cancer center. Recursive partitioning analysis (RPA) method was used to develop the refined staging systems with respect to overall survival (OS). Internal validation was performed by using calibration curve with 1000 bootstrap resampling. Performances of the RPA‐refined stages were compared against the conventional FIGO 2018 and 9th edition TNM‐stage classifications by the receiver operating characteristic curve (ROC) and decision curve analysis (DCA). Results We identified that CUI was independently prognostic for death and relapse in our cohort. RPA modeling using a two‐tiered stratification by CUI (positive and negative) and FIGO/T‐categories divided CC into three risk groupings (FIGO I′‐III'/T1′‐3′), with 5‐year OS of 90.8%, 82.1%, and 68.5% for proposed FIGO stage I′–III', respectively (p ≤ 0.003 for all pairwise comparisons), and 89.7%, 78.8%, and 68.0% for proposed T1′‐3′, respectively (p

Background: To investigate the prognostic role of pretreatment squamous cell carcinoma antigen (SCCA) in early-stage cervical cancer (CC). Methods: We enrolled 487 cases of pathology-proven early-stage [International Federation of Gynecology and Obstetrics (FIGO) I/II] squamous or adenosquamous CC that were treated from 2012 to 2015. Restricted cubic splines (RCS) with a full Cox regression model were used to evaluate the association between SCCA levels and survival outcomes. Recursive partitioning analysis (RPA) was used to construct a risk stratification model for overall survival (OS). The performance of the RPA-based model was assessed using a receiver operating characteristic (ROC) curve. Results: RCS analysis revealed an association between SCCA and OS and disease-free survival (DFS); SCCA ⩾2.5 ng/mL was robust for risk discrimination in our cohort. SCCA had an interaction effect with FIGO classification: Patients with FIGO I and SCCA ⩾2.5 ng/mL overlapped with those with FIGO II and SCCA